The Oncology Research Training Program has been in existence for 25 years and was developed with the primary goal of preparing physician-trainees for careers in academic oncology. The rationale for training in oncology research is three fold: (1) Cancer remains the leading cause of morbidity and mortality in the US;(2) There is a need to maintain momentum that has been achieved in our fundamental understanding of carcinogenesis (particularly in the molecular pathogenesis of cancer);and (3) There is a need to translate progress gained in the laboratory to the development of new strategies for the diagnosis, treatment, and prevention of cancer. Research training themes of the Program are based on the investigative interest and expertise of 28 well-established and extramurally-funded faculty members in the Division of Hematology/Oncology in the Department of Internal Medicine and the Comprehensive Cancer Center of the University of Michigan (UMCCC) (which includes faculty with appointments in other clinical and basic science departments). These research training themes in the current application are: (1) Molecular-genetic mechanisms of neoplastic transformation, aberrant signaling, and metastasis, (2) Biomarkers in cancer prevention and therapy, (3) Cancer stem cells;(4) Molecular targets of drug discovery and experimental therapeutics of cancer;and (5) Immunological approaches to cancer therapy. It is expected that trainees selected for this program will spend 2-3 years in the laboratory or relevant clinical research environment under the direct supervision of a training program faculty mentor and will develop skills in: (1) Identifying testable hypotheses that address important questions in oncology research;(2) Aquiring the necessary technical expertise to test the hypotheses identified;(3) Critically evaluating the data generated;and (4) Developing the necessary skills of written and oral communication to promulgate conclusions made. The majority of trainees will have an MD degree, 3 years of house officer training in Internal Medicine and a year of clinical subspecialty training in medical oncology/hematology. MD trainees with limited prior research experience will be encouraged to participate in an intensive 3 month postdoctoral research training program (directed and taught by Training Program faculty) to introduce them to important concepts in cellular and molecular biology. The ultimate goal of the program is to prepare trainees for careers in academic oncology as independent faculty members of schools of medicine at research universities. Lay language description: The goal of the Oncology Research Training Program is to teach MD cancer specialists-in- training the skills necessary to pursue careers in cancer research so that they can contribute to the development of advances in the prevention, diagnosis, and treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009357-30
Application #
8105173
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
1980-07-01
Project End
2012-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
30
Fiscal Year
2011
Total Cost
$303,882
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Qin, Angel; Street, Lindsay; Cease, Kemp et al. (2017) Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer 18:559-564
Qin, Angel; Gadgeel, Shirish (2017) The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions. Target Oncol 12:709-718
Decker, A M; Cackowski, F C; Jung, Y et al. (2017) Biochemical Changes in the Niche Following Tumor Cell Invasion. J Cell Biochem 118:1956-1964
Cackowski, Frank C; Eber, Matthew R; Rhee, James et al. (2017) Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy. J Cell Biochem 118:891-902
Qin, Angel; Kalemkerian, Gregory P (2016) Cisplatin, Etoposide, and Irinotecan for Relapsed Small-Cell Lung Cancer. Transl Cancer Res 5:S1142-S1144
Qin, Angel; Ramnath, Nithya (2016) The ""liquid biopsy"" in non-small cell lung cancer - not quite ready for prime time use. Transl Cancer Res 5:S632-S635
Qin, Angel; Coffey, David G; Warren, Edus H et al. (2016) Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Med 5:2567-78
Yumoto, Kenji; Eber, Matthew R; Wang, Jingcheng et al. (2016) Axl is required for TGF-?2-induced dormancy of prostate cancer cells in the bone marrow. Sci Rep 6:36520
Wood, Sherri; Feng, Jiane; Chung, Jooho et al. (2015) Transient blockade of delta-like Notch ligands prevents allograft rejection mediated by cellular and humoral mechanisms in a mouse model of heart transplantation. J Immunol 194:2899-908
Yang, Huibin; Palmbos, Phillip L; Wang, Lidong et al. (2015) ATDC (Ataxia Telangiectasia Group D Complementing) Promotes Radioresistance through an Interaction with the RNF8 Ubiquitin Ligase. J Biol Chem 290:27146-57

Showing the most recent 10 out of 36 publications